Anastasia Adamou

Anastasia Adamou

Auto-generated profile, based on publicly available information

Anastasia Adamou

First Propaedeutic Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in International Journal of Stroke
Verified
Journal Article
Closed access
AAAnastasia Adamou
Anastasia Adamou
FBFotios Barkas
Fotios Barkas
HMHaralampos Milionis
Haralampos Milionis
George NtaiosGeorge Ntaios
George Ntaios
Background: In patients surviving stroke, approximately 15% and 60% exhibit concurrent diabetes mellitus and overweight/obesity, respectively, necessitating heightened secondary prevention efforts. Despite glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrating improved outcomes for those with diabetes mellitus or obesity, their underutilization persists among eligible individuals. This systematic review and meta-analysis investigated the impact of GLP-1 RAs on stroke risk. The findings aim to optimize the implementation of this therapeutic strategy in patients surviving stroke with diabetes mellitus or obesity. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, we systematically reviewed MEDLINE and Scopus until 15 November 2023. Eligible studies included randomized cardiovascular outcome trials (CVOTs) with individuals, with or without type 2 diabetes, randomized to either GLP-1 RA or placebo. The outcomes were total strokes, non-fatal strokes, and fatal strokes. Analyses were conducted using RevMan 5.4.1. Results: Among 1369 screened studies, 11 were eligible, encompassing 82,140 participants (34.6% women) with a cumulative follow-up of 247,596 person-years. In the GLP-1 RAs group, the stroke rate was significantly lower compared to placebo (RR: 0.85, 95% CI: 0.77–0.93; NNT: 200), showing no heterogeneity or interaction with administration frequency (daily vs weekly). In addition, the GLP-1 RAs group exhibited a significantly lower rate of non-fatal strokes compared to placebo (RR: 0.87, 95% CI: 0.79–0.95; NNT: 250), with no heterogeneity or interaction based on administration frequency, route (oral vs subcutaneous), or diabetes presence. Conclusion: In this meta-analysis of 11 CVOTs with 82,140 participants, GLP-1 RAs demonstrated a 16% relative reduction in stroke risk compared to placebo. This finding may increase implementation of GLP-1 RAs by stroke specialists in individuals with stroke and comorbid diabetes mellitus or obesity. Data access statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

28 August 2023 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
IKIOANNIS KYRIAKOULIS
IOANNIS KYRIAKOULIS
AAAnastasia Adamou
Anastasia Adamou
ISIliana Stamatiou
Iliana Stamatiou
David-Dimitris ChlorogiannisDavid-Dimitris Chlorogiannis
David-Dimitris Chlorogiannis
IKIoannis Kardoutsos
Ioannis Kardoutsos
George NtaiosGeorge Ntaios
George Ntaios

7 April 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Panagiotis TasoudisPanagiotis Tasoudis
Panagiotis Tasoudis
CAChristina K. Arvaniti
Christina K. Arvaniti
AAAnastasia T. Adamou
Anastasia T. Adamou
IBIoannis Belios
Ioannis Belios
JSJohn H. Stone
John H. Stone
George NtaiosGeorge Ntaios
George Ntaios

14 February 2024 in Internal and Emergency Medicine
Verified
Journal Article
Open access
PDF file
AAAnastasia Adamou
Anastasia Adamou
David-Dimitris ChlorogiannisDavid-Dimitris Chlorogiannis
David-Dimitris Chlorogiannis
IKIOANNIS KYRIAKOULIS
IOANNIS KYRIAKOULIS
ISIliana Stamatiou
Iliana Stamatiou
DKDespoina Koukousaki
Despoina Koukousaki
George NtaiosGeorge Ntaios
George Ntaios
Sodium–glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in patients with heart failure, with or without diabetes. We sought to assess whether there is an interaction of these effects with body mass index (BMI). A systematic review of the MEDLINE and Scopus databases (last search: November 15th, 2022) was performed according to the PRISMA statement. Studies eligible for this review were randomized control trials (RCTs) with patients with chronic heart failure with either preserved or reduced ejection fraction randomly assigned to SGLT2 inhibitors or placebo. Data were extracted independently by two reviewers. BMI was classified according to the WHO classification into under/normal weight (BMI: < 25 kg/m2), overweight (BMI: 25–29.9 kg/m2), obesity class I (BMI: 30–34.9 kg/m2), and obesity classes II/III (BMI: ≥ 35 kg/m2). All analyses were performed using RevMan 5.4. Among 1461 studies identified in the literature search, 3 were eligible and included in the meta-analysis. Among 14,737 patients (32.2% were women), 7,367 were randomized to an SGLT2 inhibitor (dapagliflozin or empagliflozin) and 7,370 to placebo. There were significantly fewer hospitalizations for HF (OR: 0.70, 95%CI: 0.64–0.76), cardiovascular deaths (OR:0.86, 95%CI: 0.77–0.97) and all-cause deaths (OR:0.90, 95%CI: 0.82–0.98) in the SGLT2 inhibitors group compared to the placebo group, without any interaction with BMI group (test for subgroup differences: x2 = 1.79, p = 0.62; x2 = 0.27, p = 0.97; x2 = 0.39, p = 0.94, respectively). There is no interaction between the efficacy of SGLT2 inhibitors and BMI in patients with HF with either preserved or reduced ejection fraction. SGLT2 inhibitors are associated with improved outcomes regardless of the BMI.Trial registration: PROSPERO ID: CRD42022383643.

18 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
David-Dimitris ChlorogiannisDavid-Dimitris Chlorogiannis
David-Dimitris Chlorogiannis
Theodoros MavridisTheodoros Mavridis
Theodoros Mavridis
AAAnastasia Adamou
Anastasia Adamou
IKIOANNIS KYRIAKOULIS
IOANNIS KYRIAKOULIS
ISIliana Stamatiou
Iliana Stamatiou
George NtaiosGeorge Ntaios
George Ntaios
Current treatment options for acute ischemic stroke, including intravenous thrombolysis (IVT) and mechanical thrombectomy, have undoubtedly revolutionized stroke care. The need for additional treatment options has brought into the light direct thrombin inhibitors (DTIs) and, specifically, argatroban as a promising candidate. However, there is uncertainty regarding the safety of adding argatroban to IVT, mainly due to the increased hemorrhagic risk. In this study, we performed a systematic review and meta-analysis examining the safety and efficacy of argatroban as an add-on treatment for IVT. The following databases were searched from inception until the 14th of May 2023: Pubmed/MEDLINE, ClinicalTrials.gov, the EU Clinical Trials Register, EMBASE/Scopus, and the Cochrane Library. Only randomized clinical trials (RCTs) enrolling patients with acute ischemic stroke who underwent IVT evaluating the add-on use of any DTIs were selected for the systematic review and further meta-analysis. The PRISMA guidelines were followed at all stages. Four studies with argatroban were included in the final analysis. Analysis of risk ratio and relative risk shows that the add-on therapy with argatroban seems to be effective and favors a good clinical outcome (mRS 0–2) at 90 days, similar to that of alteplase. All studies showed a low pooled incidence of symptomatic intracerebral hemorrhage (5%), parenchymal hematoma (3%), and other major bleeding (1%). Argatroban as an add-on treatment to IVT seems not to be associated with excessive bleeding risk; however, its efficacy remains unproven. According to this synopsis of the currently available evidence, it is premature to use argatroban as an add-on to IVT treatment outside the current clinical trial setting.

1 December 2023 in European Stroke Journal
Verified
Journal Article
Closed access
MPMaurizio Paciaroni
Maurizio Paciaroni
VCValeria Caso
Valeria Caso
MRMichele Romoli
Michele Romoli
CBCecilia Becattini
Cecilia Becattini
ASAlexander Salerno
Alexander Salerno
PMPatrik Michel
Patrik Michel
Introduction: The best therapeutic strategy for patients with mechanical heart valves (MHVs) having acute ischemic stroke during treatment with vitamin K antagonists (VKAs) remain unclear. Being so, we compared the outcomes for: (i) full dose heparin along with VKA (bridging therapy group) and (ii) restarting VKA without heparin (nonbridging group). Patients and methods: For this multicenter observational cohort study, data on consecutive acute ischemic stroke patients with MHV was retrospectively collected from prospective registries. Propensity score matching (PSM) was adopted to adjust for any treatment allocation confounders. The primary outcome was the composite of stroke, systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding at 90 days. Results: Overall, 255 out of 603 patients (41.3%) received bridging therapy: 36 (14.1%) had combined outcome, compared with 28 (8.0%) in the nonbridging group (adjusted OR 1.83; 95% CI 1.05–3.18; p = 0.03). Within the bridging group, 13 patients (5.1%) compared to 12 (3.4%) in the nonbridging group had an ischemic outcome (adjusted OR 1.71; 95% CI 0.84–3.47; p = 0.2); major bleedings were recorded in 23 (9.0%) in the bridging group and 16 (4.6%) in the nonbridging group (adjusted OR 1.88; 95% CI 0.95–3.73; p = 0.07). After PSM, 36 (14.2%) of the 254 bridging patients had combined outcome, compared with 23 (9.1%) of 254 patients in the nonbridging group (OR 1.66; 95% CI 0.95–2.85; p = 0.07). Conclusion: Acute ischemic stroke patients with MHV undergoing bridging therapy had a marginally higher risk of ischemic or hemorrhagic events, compared to nonbridging patients.